Prostate Cancer Therapeutics Market By Drug Class (Chemotherapeutic agents, Immune System Modulators, Hormones, Others), By Route Of Administration (Oral, Parenteral, Other), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others), and Geography 

 

Prostate Cancer Therapeutics Market size was valued at USD 11.14 billion in 2021, growing at a CAGR of 6.6% during the forecast period 2022-2028. The prostate is an exocrine gland and found only in males.  Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. It may spread to other parts of the body mainly bones and lymph nodes. Prostate cancer is the most common type of cancer among men, but often it can be treated successfully, in initial stages it shows no symptoms but later stages it may produce pain in pelvis, difficulty in urination and furthermore, it may cause tiredness and low levels of RBC. The exact cause of prostate cancer is unknown but are generally linked to hereditary causes or to unhealthy diet and lifestyle. Studies suggest that high consumption of red meat and processed meat increases the chances of prostate cancer. Primary risk factors for prostate cancer include obesity, age and family history. Prostate cancer can be diagnosed by biopsy, prostate imaging and various other techniques. New tests such as phi test, 4Kscore test, Progensa, TMPRSS2 ERG and ConfirmMDX will be more accurate in early-stage diagnosis. This, in turn, aids in increasing the diagnosis rate and consecutively aid in the growth of the market. Prostate cancer therapeutics market has large and small players and the market is highly competitive. Players adopting acquisitions, mergers and collaborations to stenghten product offerings in prostate therapeutics market.

Key Developments: On September 17, 2019 FDA approved Apalutamide (ERLEADA, Janssen Biotech, Inc) for metastatic castration – sensitive prostate cancer (mCSPC) In 2016, October, U.S. FDA approved a supplemental new drug application for XTANDI (enzalutamide) capsules of Astellas Pharma Inc. & Pfizer Inc. to treat patients with metastatic xastration resistance prostate cancer In 2011, Johnson & Johnson has received U.S. FDA approval for ZytIGA used to treat metastatic prostate cancer.